In a statement shared with TOI, Apple said the company had resisted passing on higher costs for as long as possible.“The consumer electronics industry is facing an unprecedented challenge. The rapid ...

Early in the Covid-19 pandemic, the governor of New Jersey made an unusual admission: He’d run out of COBOL developers. The state’s unemployment insurance systems were written in the 60-year-old ...

International Business Machines stock is getting slammed Monday, becoming the latest perceived victim of rapidly developing AI technology, after Anthropic said its Claude Code tool could be used to ...

Tech workers are increasingly worried that the artificial intelligence they are building will replace them. But some are optimistic that it is just one more tool to work with. Though powerful, code ...

Java ranked third in the Tiobe Index for January 2026 at 8.71%, holding steady behind Python and C and just ahead of C++. Tiobe named C# its Programming Language of the Year for 2025 after the largest ...

Great leadership doesn’t just happen in boardrooms or business settings. From little league coaching and community initiatives to family moments and encounters with service providers, powerful ...

Recently, a friend asked me a question that's been floating around every boardroom and business school: "With AI writing code, does programming still matter?" It's a fair question. Generative AI can ...

Perl reached the top 10 after rising in popularity over the summer for reasons that aren’t immediately clear. Generative AI can be a self-fulfilling prophecy: Because gen AI scans vast amounts of data ...

Tech leaders have been adamant that artificial intelligence will forever change industries, jobs, and skills. That remains to be seen in most industries, but in the world of software engineering, AI ...

SAN FRANCISCO, June 10 (Reuters) - Enterprise software maker Linear has raised an $82 million Series C funding round valuing the startup at $1.25 billion, the company said on Tuesday. Venture capital ...

Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study. A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the ...